ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Biogen Inc

Biogen Inc (BIIB)

149,38
2,91
(1,99%)
Geschlossen 24 Dezember 10:00PM
149,38
-0,04
(-0,03%)
Nach Börsenschluss: 12:00AM

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Current Price
149,38
Gebot
149,38
Fragen
150,00
Volumen
1.534.501
145,52 Tagesbereich 149,92
145,0709 52-Wochen-Bereich 268,74
Marktkapitalisierung
Handelsende
146,47
Handelsbeginn
146,47
Letzte Trade
1
@
149.4
Letzter Handelszeitpunkt
Finanzvolumen
US$ 227.597.833
VWAP
148,3204
Durchschnittliches Volumen (3 Mio.)
1.567.515
Ausgegebene Aktien
145.719.340
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
18,75
Gewinn pro Aktie (EPS)
7,97
Erlöse
9,84B
Nettogewinn
1,16B

Über Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vume... Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. Mehr anzeigen

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Website
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker BIIB. The last closing price for Biogen was US$146,47. Over the last year, Biogen shares have traded in a share price range of US$ 145,0709 to US$ 268,74.

Biogen currently has 145.719.340 shares in issue. The market capitalisation of Biogen is US$21,34 billion. Biogen has a price to earnings ratio (PE ratio) of 18.75.

Option-Flow Biogen (BIIB)

Gesamtfluss

Bärisch

Nettoprämie

-15M

Calls / Puts

10,42%

Käuf. / Verkä.

120,83%

OTM / ITM

12,77%

Sweeps

0,00%

BIIB Neueste Nachrichten

"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico

"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico PR Newswire TOKYO and CAMBRIDGE, Mass., Dec. 4, 2024 TOKYO and CAMBRIDGE, Mass., Dec. 4, 2024...

"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea PR Newswire TOKYO and CAMBRIDGE, Mass., Nov. 27, 2024 TOKYO and CAMBRIDGE, Mass., Nov. 27, 2024...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease PR Newswire TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 TOKYO and CAMBRIDGE, Mass...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.380.255033557047149154.24145.07092439361147.7300948CS
4-10.61-6.63166447903159.99165.285145.07091660504154.12118448CS
12-44.45-22.9324665944193.83195145.07091567515168.8235112CS
26-76.36-33.826526092225.74238145.07091263346185.66436218CS
52-109.12-42.2127659574258.5268.74145.07091207175203.86752112CS
156-83.57-35.8746512127232.95319.76145.07091186472235.37315474CS
260-153.52-50.6833938594302.9468.2499145.07091314850263.4838148CS

BIIB - Frequently Asked Questions (FAQ)

What is the current Biogen share price?
The current share price of Biogen is US$ 149,38
How many Biogen shares are in issue?
Biogen has 145.719.340 shares in issue
What is the market cap of Biogen?
The market capitalisation of Biogen is USD 21,34B
What is the 1 year trading range for Biogen share price?
Biogen has traded in the range of US$ 145,0709 to US$ 268,74 during the past year
What is the PE ratio of Biogen?
The price to earnings ratio of Biogen is 18,75
What is the cash to sales ratio of Biogen?
The cash to sales ratio of Biogen is 2,21
What is the reporting currency for Biogen?
Biogen reports financial results in USD
What is the latest annual turnover for Biogen?
The latest annual turnover of Biogen is USD 9,84B
What is the latest annual profit for Biogen?
The latest annual profit of Biogen is USD 1,16B
What is the registered address of Biogen?
The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810
What is the Biogen website address?
The website address for Biogen is www.biogen.com
Which industry sector does Biogen operate in?
Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
DRCTDirect Digital Holdings Inc
US$ 5,25
(854,55%)
68,54M
CHEKCheck Cap Ltd
US$ 2,24
(279,66%)
40,03M
SLGLSol Gel Technologies Ltd
US$ 1,57
(265,97%)
18,2M
RELIReliance Global Group Inc
US$ 3,08
(156,67%)
105,56M
TRAWTraws Pharma Inc
US$ 12,50
(149,00%)
28,23M
AILEiLearningEngines Inc
US$ 0,199
(-77,51%)
29,71M
MGOLMGO Global Inc
US$ 0,4765
(-49,84%)
14,17M
YHCLQR House Inc
US$ 1,11
(-36,57%)
1,28M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,4014
(-34,37%)
195,36M
ADGMAdagio Medical Holdings Inc
US$ 1,095
(-33,64%)
4,84M
EDBLEdible Garden AG Inc
US$ 0,3669
(54,35%)
410,01M
RGTIRigetti Computing Inc
US$ 10,945
(16,81%)
229,36M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,4014
(-34,37%)
195,36M
NVDANVIDIA Corporation
US$ 139,67
(3,69%)
175,95M
RIMEAlgorhythm Holdings Inc
US$ 0,0925
(21,07%)
155,99M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock